The battle over abortion drugs is being fought on three fronts at once: state attorneys general are suing the FDA to roll back access to mifepristone, the Trump administration has opened a new safety review that could reimpose old restrictions, and officials are weighing whether to revive an 1873 federal statute that would make it a crime to mail the pills. For now, mifepristone remains FDA-approved through 10 weeks of pregnancy, can be prescribed by telehealth, and can be mailed from a certified pharmacy. None of that is guaranteed to last.
What Is Actually Legal Right Now
The rules in effect today come from a REMS modification the FDA finalized on January 3, 2023. That change permanently removed the requirement that patients pick up mifepristone in person, allowed certified retail and mail-order pharmacies to dispense it for the first time, and confirmed that telehealth prescribing is permissible.1U.S. Food and Drug Administration. Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation The approved use is for ending a pregnancy through 70 days of gestation, and the regimen is a single 200 mg tablet of mifepristone followed by 800 mcg of misoprostol 24 to 48 hours later.2Food and Drug Administration. Clinical Review NDA 020687/S-020 Mifeprex
State law is a separate layer. Nearly half of U.S. states have banned or severely restricted abortion since Dobbs, and most of those restrictions apply to medication abortion. The FDA’s own guidance directs questions about state refusals to the Department of Justice, which concedes that the federal agency cannot by itself override state prohibitions.3U.S. Food and Drug Administration. Questions and Answers on Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation So the practical question for any given patient is two-part: what the FDA permits, and what the state they live in permits.
How Patients Get Mifepristone Today
The prescriber has to be certified. A healthcare provider who wants to prescribe mifepristone must sign a Prescriber Agreement Form, review the risks with the patient, and obtain a signed Patient Agreement. Since 2016, that provider no longer has to be a physician: nurse practitioners, nurse midwives, and physician assistants can prescribe as well.2Food and Drug Administration. Clinical Review NDA 020687/S-020 Mifeprex
The pharmacy has to be certified too. Pharmacies dispensing mifepristone must designate an authorized representative, complete a Pharmacy Agreement Form, and show they can receive prescriptions by email or fax and ship with tracking. The REMS runs as a closed system: every prescriber, pharmacy, and distributor is verified before any mifepristone changes hands.3U.S. Food and Drug Administration. Questions and Answers on Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation Once both ends of that system are in place, a prescription can be filled at a certified pharmacy in person or mailed to the patient.
What the Supreme Court Settled, and What It Did Not
In June 2024, the Supreme Court unanimously rejected the first post-Dobbs challenge to mifepristone in FDA v. Alliance for Hippocratic Medicine. Justice Kavanaugh, writing for the Court, held that the plaintiff doctors lacked Article III standing because they do not prescribe, manufacture, sell, or use the drug, so the FDA’s actions did not injure them directly. Their theory that loosened regulations would eventually send more patients with complications to their emergency rooms was too speculative, and federal conscience protection laws already shield doctors from being forced to perform abortions against their beliefs.4Supreme Court of the United States. FDA v. Alliance for Hippocratic Medicine (23-235)
The ruling preserved the FDA’s current regulations, but it did not decide whether those regulations are lawful. The Court held only that these particular plaintiffs were the wrong ones to bring the case. Parties with a cleaner claim of injury were free to try again, and they did.
The New State Attorney General Lawsuits
At least three separate cases filed by state attorneys general are now challenging the FDA’s mifepristone regulations, and states can more easily show the direct injury the Supreme Court found missing before.
The most closely watched was filed in October 2025 by the attorneys general of Louisiana, Idaho, and Missouri in a Louisiana federal court. It targets the January 2023 REMS modification and asks the court to restore the in-person dispensing requirement and shut down pharmacy and mail-order distribution. At a February 2026 hearing, the judge allowed GenBioPro, the generic manufacturer, to intervene in defense of the regulations but did not immediately rule on the states’ request for a preliminary injunction. The Department of Justice has asked the court to pause the case while the FDA conducts what it describes as a new safety review of mifepristone.
In a separate suit, Missouri, Kansas, and Idaho are challenging the FDA’s original 2000 approval in a Missouri federal court. Florida and Texas have filed a similar challenge in Texas. If any of these cases succeed, the effect would be nationwide. A court order invalidating the approval or reimposing earlier restrictions would reach every state, not just the ones that filed.
The Comstock Act Threat
A 19th-century federal statute hangs over the entire mail-order framework. Section 1461 of title 18 of the U.S. Code, enacted in 1873 as part of the Comstock Act, declares “every article or thing designed, adapted, or intended for producing abortion” to be nonmailable. Violations carry up to five years in prison for a first offense and up to ten for subsequent ones.5Office of the Law Revision Counsel. 18 U.S. Code 1461 – Mailing Obscene or Crime-Inciting Matter
In December 2022, the Justice Department’s Office of Legal Counsel formally concluded that Section 1461 does not prohibit mailing prescription drugs that can be used for abortions, as long as the sender does not intend them to be used unlawfully. Because abortion remains legal in many states, OLC reasoned, mailing the pills does not by itself show unlawful intent.6United States Department of Justice. Application of the Comstock Act to the Mailing of Prescription Drugs That Can Be Used for Abortions
That opinion was issued under the Biden administration. The Trump administration has appointed officials to the Office of Legal Counsel who previously called publicly for revoking it and enforcing the Comstock Act against mail-order abortion. No formal reversal had been issued as of late 2025. If one comes, the practical effect could be a nationwide ban on mailing mifepristone regardless of whether the sending or receiving state permits abortion.
State Bans Versus FDA Approval
Can a state ban a drug that the FDA has approved as safe and effective? The answer turns on whether federal drug approval preempts conflicting state laws under the Supremacy Clause, and neither Congress nor the Supreme Court has definitively settled that question for abortion drugs.
The preemption argument is that the FDA’s authority under the Federal Food, Drug, and Cosmetic Act occupies the field: once the agency approves a drug and sets conditions for its distribution, states cannot override that judgment with a ban. GenBioPro pressed this theory in a suit against West Virginia’s abortion law. The opposing view is that states have long-standing authority to regulate medical practice within their borders and that nothing in the FDA’s enabling statute expressly displaces state abortion laws. The cases moving through federal court now could force a ruling.
Shield Laws for Providers
More than 20 states and Washington, D.C. have enacted shield laws protecting healthcare providers who offer reproductive care from legal consequences imposed by other states. The protections vary but can include refusing out-of-state extradition requests, declining to discipline professional licenses, blocking civil lawsuits, and refusing to enforce another state’s court judgments. At least eight states have shield laws that explicitly cover providers who prescribe by telehealth to patients in states with bans.
These laws create a meaningful but partial safety net. A provider in a shield state can prescribe and mail mifepristone to a patient in a restrictive state with reasonable confidence that their own state will not help prosecute them. The patient may still face exposure under their home state’s law. And the whole arrangement rests on the Comstock Act remaining dormant: a federal mailing prohibition would override a state shield.
Misoprostol as a Backup
Misoprostol, the second pill in the standard two-drug regimen, carries far fewer legal and regulatory obstacles than mifepristone. The FDA approved it decades ago for preventing stomach ulcers. It is not subject to a REMS and is stocked at ordinary pharmacies. Legal restrictions targeting mifepristone specifically do not automatically reach it.
Medical research supports using misoprostol alone, though it is less effective than the combination. The mifepristone-misoprostol regimen succeeds roughly 95 percent of the time. An updated misoprostol-only protocol, involving multiple 800 mcg doses taken over several hours, has shown completion rates of about 82 to 95 percent across studies, depending on dosing and how success is measured. The tradeoff is a higher rate of side effects and a greater chance of needing a follow-up procedure. If mifepristone access narrows, misoprostol-only protocols become the fallback.
What It Costs
A medication abortion can run roughly $800 out of pocket, though many patients pay less depending on where they are seen and what their insurance covers. Private insurance coverage varies by plan and by state, and some plans exclude abortion entirely.
The largest coverage gap is the Hyde Amendment, a rider attached to federal spending bills since 1976 that prohibits using federal funds for abortion except when the pregnancy threatens the mother’s life or results from rape or incest. Medicaid will not pay for medication abortion in most circumstances, which hits the lowest-income patients hardest.7United States Department of Justice. Reconsidering the Application of the Hyde Amendment to the Provision of Transportation for Women Seeking Abortions
In January 2025, the Trump administration issued an executive order directing all federal agencies to end the use of taxpayer funds to “fund or promote elective abortion.” The order rescinded two Biden-era executive orders that had expanded federal support for abortion access, including one the administration said had allowed Medicaid funding for travel costs.8The White House. Fact Sheet: President Donald J. Trump Enforces Overwhelmingly Popular Demand to Stop Taxpayer Funding of Abortion
Some states use their own funds to cover abortion through Medicaid, but most do not. For patients living in states with bans and no state-funded coverage, the financial barrier compounds the geographic one: traveling to another state, taking time off work, and paying the full cost out of pocket. That is the part of the fight that decides who can actually use rights that still exist on paper.